Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2024 | Tailoring radiation therapy for breast cancer based on recurrence risk

Orit Kaidar-Person • 16 May 2024
ESMO Breast 2024
Breast Cancer

Orit Kaidar-Person, MD, Sheba Medical Center, Ramat Gan, Israel, discusses how radiation therapy for breast cancer can be tailored based on recurrence risk. Meta-analyses, including recent updates published in the Lancet, show the significance of radiation to regional nodes for reducing recurrence and breast cancer mortality. Current studies aim to stratify patients to identify those who will benefit most, particularly those with positive lymph nodes. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Orit Kaidar-Person

The role of regional node irradiation for low-burden breast cancer
0:53
The role of regional node irradiation for low-burden breast cancer
Orit Kaidar-Person • 13 Mar 2025
Do all low-burden breast cancer cases need regional node irradiation?
0:50
Do all low-burden breast cancer cases need regional node irradiation?
Orit Kaidar-Person • 13 Mar 2025
Indicating radiotherapy after breast-conserving therapy & mastectomy
1:28
Indicating radiotherapy after breast-conserving therapy & mastectomy
Orit Kaidar-Person • 13 Mar 2025
Unanswered questions in early breast cancer care at St Gallen 2025
0:40
Unanswered questions in early breast cancer care at St Gallen 2025
Orit Kaidar-Person • 13 Mar 2025

Related Videos

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
1:30
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park • 31 May 2026
The content of VJOncology is intended for healthcare professionals